Gene and stem cell therapies have been touted as the next phase in the longevity movement, with promises to rejuvenate the body at the cellular level and reverse the effects of ageing. But, as the prospect of life extension moves into the mainstream, it presents big questions for society as a whole. Are we ready for a world where people live much longer lives?

In this final episode, the FT’s Michael Peel and Hannah Kuchler dive into the tough moral questions at the heart of the longevity movement. Hannah speaks to the team at Fountain Life, a longevity clinic trying to bring stem cell therapy to the middle classes. We meet Daniel Ives, founder of gene therapy company Shift Bioscience, and Liz Parrish, who has self-experimented with gene therapies through her company, Biovia. Finally, Michael speaks to Arthur Caplan, the head of the ethics board of longevity fund, Hevolution.

Free to read:

From immortal jellyfish to elephants: scientists probe secrets of long-lived animals

Inside the billion-dollar quest to live beyond 100

Gene editing breakthrough promises to boost fight against disease

This series of Tech Tonic is hosted by Michael Peel and Hannah Kuchler. It is produced by Josh Gabert-Doyon. The senior producer is Edwin Lane. Flo Phillips is the executive producer. Sound design by Breen Turner and Samantha Giovinco. Fact checking by Simon Greaves, Lucy Baldwin and Tara Cromie. Original music by Metaphor Music. Manuela Saragosa is the FT’s acting co-head of audio. Special thanks to Michela Tindera.

Clips: Al Jazeera Balkans, TV France Japon, ABP News, Rome Reports, @Sciencerely

The FT does not use generative AI to voice its podcasts.

Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.

Defying death: The future of forever

FT Tech Tonic